Abstract: Cyclometalated (C^N^C)Au(III) complexes bearing functionalized N-heterocyclic carbene (NHC) ligands provide a highyielding, modular route to bioconjugated and binuclear complexes. This methodology has been applied to the synthesis of bioconjugated complexes presenting biotin and 17α-ethynylestradiol vectors, as well as to the synthesis of bimetallic Au(III)/Au(I) complexes. The in vitro antiproliferative activities of these compounds against various cancer cells lines depend on the linker length, with the longer linker being the most potent. The estradiol conjugate AuC6Estra proved to be more toxic against the estrogen receptor positive (ER+) cancer cells than against the ER-cancer cells and non-cancer cells. The bimetallic complex AuC6Au was more selective for breast cancer cells with respect to a healthy cell standard than the monometallic complex AuNHC. The metal uptake study on cells expressing or not biotin and estrogen receptors revealed an improved and targeted delivery of gold for both the bioconjugated complexes AuC6Biot and AuC6Estra compared to the non-vectorised analogue AuNHC. The investigations of the interaction of the bioconjugates and bimetallic complexes with human telomeric G-quadruplex DNA using FRET-melting techniques revealed a reduced ability to stabilize this DNA structure with respect to the non-vectorised analogue AuNHC.
Introduction
Cyclometallated Au(III) complexes have attracted significant interest in the last decade for a large palette of applications including fundamental gold chemistry investigations, [1] photoemissive materials [2] and biological applications. [3] Bis-cyclometallated (C^N^C)Au(NHC) complexes have appeared as particularly promising anticancer agents (see Figure 1 for examples). [4] Those complexes have been indicated to enhance topoisomerase 1 induced DNA cleavage, [4a] to downregulate protein synthesis pathways [4c] and to stabilize G-quadruplex and i-motif structures in DNA (Figure 1 , type A and B). [5] We have demonstrated that a pyrazine-based [(C^N pz^C )Au(NHC)] + complex (AuNHC in Figure 1 ), which presents low-to sub-micromolar IC50 values on various cancer cell lines, was highly stable toward reduction and substitution in physiological environments, even in the presence of glutathione. However, its low selectivity for cancer cells with respect to healthy ones remains a challenge. [5] Modifying the NHC ligand in structure B (Figure 1 ), e.g. by decorating substituents R 1 , R 2 with suitable vectors, seemed a promising strategy to improve the selectivity for cancer cells and to decrease potential side effects. Conjugation to biological vectors and use of polynuclear compounds have been shown to lead to increases in the selectivity and toxicity of anticancer drugs. [6, 7, 8, 9] To this end, we recently investigated the synthesis of amino ester-decorated (C^N pz^C )Au(III) acyclic carbene complexes ( Figure 1 , type C), made by the nucleophilic attack by the corresponding amino esters on cationic (C^N pz^C )Au(III) isocyanide complexes. However, although that methodology was successful when using amino esters, the requirement to work under perfectly anhydrous conditions precluded the use of more elaborate biomolecules. Moreover, those acyclic carbene complexes were found to be much less stable toward GSH than cyclic NHC-based complexes. [10] Imidazole-and benzimidazole-type NHC ligands bearing pentafluorophenol ester moieties have already been successfully used for grafting organometallic Ru(II) and Au(I) complexes onto peptides, [11] aptamers [12] and for the synthesis of bimetallic complexes.
[13] The synthesis of bioconjugated metal complexes often requires considerable synthetic efforts in order to achieve modularity in terms of potential vectors and also in terms of linkers between the pharmacophore and the vector. [14] Thus, using an NHC ligand featuring a pentafluorophenol ester group to build a single scaffold for the bioconjugation of different vectors or metal-based fragment onto a (C^N pz^C )Au(III) core could lead to large library of biologically relevant compounds in only few synthetic steps.
Figure 1: Examples of [(C^N^C)Au(NHC)]
+ complexes investigated for anticancer purposes. [4a,5,10] Here we report a high-yield three-step procedure for the synthesis of bioconjugated and bimetallic complexes using a common 
Results and Discussion
Synthesis and characterization. The synthetic route is shown in Scheme 1. Complex 2 was obtained in 70% yield by the classical transmetallation method, starting by reacting the benzimidazolium salt with silver oxide to afford the silver-NHC complex, followed by NHC transfer to (C^N pz^C )AuCl. The reaction of 2 with diaminoalkanes of different chain lengths (i. e. ethylenediamine, 1,4-diaminobutane, and 1,6-diaminohexane) in refluxing acetonitrile gave high isolated yields of the corresponding [(C^N . All these features are in good agreement with reported reactions. [13] Scheme 1: Synthesis of the complexes AuCnNH2 (n = 2, 4, 6).
The AuCnNH2 complexes were converted to bioconjugated and binuclear complexes as shown in Scheme 2. Biotin has already been used for the targeting of taxol [15] and metal complexes. [4c,16] corresponding, respectively, to the urea and amide functional groups. The formation of the expected conjugates was further confirmed by high resolution mass spectrometry, which showed in each case the molecular monocation and the dicationic adducts with sodium or potassium. Estradiol/metal complex conjugates have been used to target estrogen receptor positive (ER+) cells. [14a,17] By reacting the AuCnNH2 complexes with the 17α-ethynylestradiol-NHS precursor 4 at room temperature in acetonitrile in presence of a base, the Au(III)/estradiol conjugates AuCnEstra (n = 2, 4, 6) were obtained in good isolated yield (Scheme 2). Those yields were more than 25% higher than the previously reported coupling methods between metal-NHC complexes and estradiol derivatives using rutheniumcatalyzed alkyne-azide cycloaddition. [17a] The formation of the bioconjugated species was indicated in the + core and the estradiol vector, together with the disappearance of the signal of the NHS group. IR spectroscopy showed in all cases only one signal for the carbonyl function, as previously seen for the biotin conjugates. The formation of the expected conjugates was also confirmed by high resolution mass spectrometry, which in each case showed the molecular cation. Few studies have reported mixed valence Au(I)/Au(III) complexes and, to the best of our knowledge, never with organogold fragments.
[18] By reacting the AuCnNH2 complexes with the Au(I)-NHC precursor 5 in acetonitrile at room temperature, the mixed valence binuclear complexes AuCnAu (n = 2, 4, 6) were obtained with very high isolated yields (Scheme 2). The 1 H NMR spectra of the binuclear complexes displayed a 1/1 ratio between the signals of the Au(III) and Au(I) fragments, a signal for a second amide proton and the quasi-equivalence of the two CH2 groups in α position with respect to the amides. The (Figure 2 ). The formation of the expected bimetallic complexes was also confirmed by high resolution mass spectrometry which showed in each case the molecular monocation and the dication resulting from the loss of the chloride ligand.
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Scheme 2: Synthesis of the bioconjugated complexes AuCnBiot and AuCnEstra (n = 2, 4, 6) and the binuclear complexes AuCnAu (n = 2, 4, 6). Evaluation of antiproliferative activity. All conjugated and binuclear compounds were screened at concentrations of 100 µM and 10 µM against MCF-7 cells, which are known to express both biotin and estrogen receptors. [14a,15] Cell viability was measured after 72 hours Figure 3 : Inhibition of MCF-7 cells proliferation by complexes A) AuCnBiot (n = 2, 4, 6); B) AuCnEstra (n = 2, 4, 6); C) AuCnAu (n = 2, 4, 6). Data represent the average ± standard deviation of three experiments. The significance of the results was analysed by t-test. *p value < 0.05; **p value < 0.01; ***p value < 0.001.
The data show a correlation between the length of the alkyl linker and the toxicity of the respective systems, with the C6 complexes being significantly more toxic than the C2 and C4 congeners, except for the AuCnAu complexes where the difference between the C6 and C4 compounds is not significant. For that reason AuC6Biot, AuC6Estra and AuC6Au were selected for further cytotoxic investigations. The complexes AuC6Biot and AuC6Estra were tested on panels of cells expressing or not expressing biotin receptors (BR) and estrogen receptors (ER), respectively. Tests on normal healthy fibroblasts were included for comparison. Results are reported in Table 1 . The antiproliferative profile of AuC6Biot does not seem to depend on the expression of the biotin receptors (Table 1) . Indeed, AuC6Biot appeared only marginally more potent against some of the BR+ cell lines (MCF-7 and MDA-MB-231) than against BR-cell lines or the healthy fibroblasts (MRC5) (IC50 = 8.9 ± 0.7; 9.6 ± 1.6; 11.2 ± 0.9; 10.3 ± 0.4 and 11 ± 5 μM against MCF-7, MDA-MB-231, HCT-116, HEK-293 and MRC-5 cells respectively). The introduction of the polar biotin substituent into the NHC framework greatly reduced the cytotoxicity, e.g. against MCF-7 by a factor of ~16 compared to AuNHC. Moreover AuC6Biot appeared completely non-toxic against A549 cells although these are reported to largely express biotin receptors. [15] A different situation was encountered in the case of AuC6Estra. This complex was tested against MCF-7 (ER+), MDA-MB-231 (ER-) and MRC-5 (healthy fibroblasts) cells (Table 1 ). The antiproliferative effect of AuC6Estra against the ER+ cells was slightly higher than against the ER-and non-cancer cells. This may suggest a possible targeting effect of the 17α-ethynylestradiol vector.
Interestingly, AuC6Au presented a specificity for the breast cancer cell lines MCF-7 and MDA-MB-231 (IC50 = 13.7 ± 2.2 and 9.2 ± 2.9 μM, respectively) compared to the other cancer cells A549 (lung) and HCT116 (colon) (IC50 > 100 μM in both cases) ( Table 1) . AuC6Au showed the same ratio between its IC50 values against MCF-7 cells and healthy fibroblasts (IC50 = 38.1 ± 5.7 μM) as AuNHC. Moreover, the IC50 value of AuC6Au was four times lower against MDA-MB-231 cells than against MRC-5 cells. This contrasts with the unsubstituted Au(III) complex AuNHC which proved four times more toxic against healthy fibroblasts than against MDA-MB-231 cells. The results demonstrate a promising increase in anticancer selectivity as a result of NHC modification. 
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.Cellular gold uptake. Drug uptake and intracellular metal accumulation has been demonstrated to be one of the main factors limiting drug efficacy. [19] The role of biovectors on the uptake of metal-based drugs can be quantified using inductively coupled plasma-mass spectrometry techniques (ICP-MS); this method has already been used in order to assess the role of biovectors on the uptake of metal-based drugs. [20] We investigated the impact of the vectors and the presence of a second gold centre on the accumulation of our complexes by measuring the gold uptake in MCF-7 cells (ER+ and BR+), HCT-116 (BR-) and MDA-MD-231 (ER-). The results are depicted in Figure 4 .
Figure 4: Impact of the vector and second gold center on the cell uptake by A) MCF-7 (BR+) and HCT-116 (BR-) cells; B) MCF-7 (ER+) and MDA-MB-231 (ER-) cells after 6 hours of treatment with 10 µM of compounds in DMSO; data represent the average and standard deviations of three experiments. The significance of the results was analyzed by t-test. *p value < 0.05; **p value < 0.01.
Interestingly, both the biotin and 17α-ethynylestradiol vector improved the gold uptake with respect to the non-conjugated complex AuNHC. Moreover, for both AuC6Biot and AuC6Estra the cells expressing the corresponding receptors (BR for AuC6Biot and ER for AuC6Estra) presented a significantly higher intracellular gold content than the cells not expressing the receptors. This suggests the potential of using such vectors to effectively and selectively deliver metal-based compounds to selected cancer cells. However, despite the enhanced intracellular accumulation, both AuC6Biot and AuC6Estra appeared less cytotoxic than AuNHC, which suggests that cell uptake might not be the limiting factor for those compounds. In contrast, despite having two gold atoms per molecule, AuC6Au showed a reduced intracellular concentration of gold in all cancer cells with respect to the mono-gold complex AuNHC. This is in line with the reduced antiproliferative activity of AuC6Au. Moreover, AuC6Au presented a significantly reduced gold uptake in HCT-116 cells where it demonstrated no antiproliferative activity.
Interaction with DNA G-quadruplex. G-quadruplexes are secondary structures of DNA formed by stacking of tetrads of guanines residues linked via Hoogsteen hydrogen-bonding and stabilized by the presence of typically monovalent cations in the center of the tetrad. [21] We recently reported on the ability of AuNHC to stabilize the G-quadruplex structure of DNA as a possible intracellular target for these class of compounds. [5] To highlight the impact of the vectors and the second gold centre on the interaction of the [(C^N pz^C )Au(NHC)] + core with potential targets, AuC6Biot, AuC6Au, AuC6Estra and AuC6NH2 were screened against the human telomeric G-quadruplex sequence (5ʹ-GGG-TTA-GGG-TTA-GGG-TTA-GGG-3ʹ, hTeloG) at pH 7.2 by a FRET-based DNA melting assay (see Experimental). The results are presented in Figure 5 .
Figure 5:
Stabilization of human telomeric DNA G-quadruplex sequence (hTeloG, 0.2 µM) in 10 mM socium cacodylate, 100 mM NaCl at pH 7.2 by complexes AuNHC, AuC6NH2, AuC6Biot, AuC6Au and AuC6Estra at 1 µM measured by FRET-DNA melting assay; data represent the average and standard deviations of three experiments. The significance of the results was analyzed by t-test. **p value < 0.01; ***p value < 0.001.
Compared to the parent compound, AuNHC, we could observe a reduced interaction with hTeloG due to the presence of the long 1,6-diaminohexane linker (ΔTm = 3.6 ± 0.8°C for AuC6NH2). Furthermore the presence of the two vectors reduced even more the interaction with hTeloG with respect to AuC6NH2 (ΔTm = 1.6 ± 0.6; 1.4 ± 0.6°C for AuC6Biot and AuC6Estra respectively). Interestingly, although NHC-Au(I)-Cl compounds have been reported not to stabilize Gquadruplex structures, [22] the presence of the second gold centre enhanced the interaction with hTeloG with respect to AuC6NH2 (ΔTm = 6.0 ± 0.3°C for AuC6Au) and was close to the strength of the 10.1002/chem.201705902 Accepted Manuscript
Chemistry -A European Journal
This article is protected by copyright. All rights reserved. target. This inhibition of interaction may be correlated with the observed decreased antiproliferative activity. On the contrary, having a second gold centre does not dramatically reduce the interaction with the target but decreased the cell uptake, resulting also in a generally reduced antiproliferative activity.
Conclusions
In summary, the synthesis of a library of bioconjugated and binuclear [(C^N pz^C )Au(NHC)] + complexes has been achieved in high yields employing a modular approach from a common Au(III) scaffold. This has allowed the easy screening of several molecular design parameters such as the linker length, the biological vector used and the number of metal centres. While the biotin and 17α-ethynylestradiol vectors improved and targeted the gold uptake to cells expressing the relevant receptors, they did not increase the antiproliferative activities, likely due to a reduction in the interaction of these sterically more hindered complexes with possible intracellular targets. By contrast, the reduced activity of the bimetallic complex AuC6Au was mainly driven by a reduced intracellular accumulation. On the other hand, AuC6Au was up to 4.1 times more toxic towards MDA-MB-231 cancer cells than towards healthy cells. Further studies are ongoing to increase the activity of the complexes by introducing "self-immolative" linkers [23] [2c, 12, 24, 25] Synthesis and characterization
A mixture of 1 (45 mg, 0.087 mmol) and Ag2O (20 mg, 0.087 mmol) was stirred in distilled dichloromethane (20 mL) at room temperature in the dark for 6 h. (C^N pz^C )AuCl (50 mg, 0.087 mmol) and KPF6 (49 mg, 0.261 mmol) were added to the mixture and the reaction was stirred overnight at room temperature in the dark. The obtained yellow solution was filtered through Celite and the solvent was removed in vacuo to give a yellow film. Upon washing with light petroleum a yellow powder was formed which was collected and dried to afford the pure product (68 mg, 0.061 mmol, 70 % yield [(C^N pz^N )Au(1-methyl-3-(4-(2-aminoethyl)carboxamid)benzylbenzi midazol-2-ylidene)]PF6 (AuC2NH2) A mixture of 2 (250 mg, 0.22 mmol) and ethylenediamine (0.3 mL, 4.4 mmol) was stirred in distilled acetonitrile (20 mL) at 80 C for 3 h. After the solution was cooled to room temperature, acetonitrile was removed under vacuum, leaving an orange oily solid which was dissolved into dichloromethane. The organic phase was washed twice with a saturated aqueous NaHCO3 solution and twice with water. After drying over Na2SO4, the solvent was partially evaporated. Upon addition of light petroleum an orange precipitate was formed which was collected and dried to afford the pure product as an orange powder (208 mg, 0. [(C^N pz^N )Au(1-methyl-3-(4-(4-aminobutyl)carboxamid)benzylbenzi midazol-2-ylidene)]PF6 (AuC4NH2) Following the procedure described for AuC2NH2, the compound was made from 2 (200 mg, 0.17 mmol) and 1,4-diaminobutane (302 mg, 3.4 mmol) and obtained as an orange powder (155 mg, 0.15 mmol, 89 % yield). Anal. Calcd for C44H50N6OAuPF6 (1020.9): C, 51.77; H, 4.94; N, 8.23. Found: C, 51.65; H, 4.86; N, 8.31 [(C^N pz^N )Au(1-methyl-3-(4-(6-aminohexyl)carboxamid)benzylbenzi midazol-2-ylidene)]PF6 (AuC6NH2) Following the procedure described for AuC2NH2, the compound was made from 2 (153 mg, 0.13 mmol) and 1,6-diaminohexane (304 mg, 2.6 mmol) and obtained as an orange powder (122 mg, 0.12 mmol, 89 % yield). Anal. Calcd for C46H54N6OAuPF6 (1048.9): C, 52.67; H, 5.19; N, 8.01. Found: C, 52.57; H, 5.31; N, 7.96 [(C^N pz^N )Au(NHC-C2-biotin)]PF6 (AuC2Biot) AuC2NH2 (40 mg, 0.040 mmol) and Biotin-NHS (14 mg, 0.040 mmol) were dissolved in dry DMF (0.5 mL). The reaction was stirred at room temperature overnight. Upon addition of diethyl ether an orange precipitate was formed, which was collected and recrystallized from a mixture dichloromethane/light petroleum to give the pure compound as an orange powder (49 mg, 0.039 mmol, 99 % yield). Anal. Calcd for C52H60N8O3SAuPF6 (1219.1): C, 51. 23; H, 4.96; N, 9.19. Found: C, 51.15; H, 4.98; N, 9.12 . IR (cm .
[(C^N pz^N )Au(NHC-C6-biotin)]PF6 (AuC6Biot) Following the procedure described for AuC2Biot, the compound was made from AuC6NH2 (40 mg, 0.038 mmol) and Biotin-NHS (13 mg, 0.038 mmol) and obtained as a yellow powder (47 mg, 0.037 mmol, 97 % yield). Anal. Calcd for C56H68N8O3SAuPF6.2H2O (1329.3): C, 51.26; H, 5.61; N, 8.54. Found: C, 51.47; H, 5.94; N, 8.12 . IR (cm [(C^N pz^N )Au(NHC-C2-ethynylestradiol)]PF6 (AuC2Est) AuC2NH2 (32 mg, 0.032 mmol) and ethynylestradiol-NHS (17 mg, 0.032 mmol) were dissolved in dry acetonitrile (1 mL) and K2CO3 (9 mg, 0.064 mmol, 2 eq.) was added. The mixture was stirred at room temperature overnight. The solvent was removed under vacuum and the residue dissolved in dichloromethane. After filtration, the dichloromethane solution was concentrated under vacuum. Upon addition of diethyl ether a pale yellow precipitate was formed which was collected and recrystallized from a mixture dichloromethane/light petroleum to give the pure compound as a yellow powder (34 mg, 0.025 mmol, 76 % yield). Anal. Calcd for C69H74N6O4AuPF6·2H2O (1427.3): C, 58.06; H, 5.37; N, 5.89. Found: C, 57.99; H, 5.28; N, 6.35 . IR (cm 8.05 (s, 3 H, CHarom.), 7.79 (d, 3 JH-H = 7. 8 Hz, 2 H, CHarom.), 7.62 (m , 4 H, CHarom.), 7.37-7.47 (m, 5 10.1002/chem.201705902 Accepted Manuscript
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This article is protected by copyright. All rights reserved. [(C^N pz^N )Au(NHC-C4-ethynylestradiol)]PF6 (AuC4Est) Following the procedure described for AuC2Estra, the compound was made from AuC4NH2 (40 mg, 0.039 mmol), ethynylestradiol-NHS (20 mg, 0.039 mmol) and K2CO3 (11 mg, 0.078 mmol) and obtained as a yellow powder (37 mg, 0.026 mmol, 67 % yield). Anal. Calcd for C71H76N6O4AuPF6. 8H2O (1563.5): C, 54.54; H, 5.93; N, 5.38. Found: C, 54.56; H, 4.50; N, 5.18 . IR (cm [(C^N pz^N )Au(NHC-C2-NHC-AuCl)]PF6 (AuC2Au) AuC2NH2 (45 mg, 0.045 mmol) and {MeBzim(Bz-4-CO2(C6F5))}AuCl (30 mg, 0.045 mmol, 1 eq.) were stirred in distilled acetonitrile (6 mL) at room temperature for 5 h in the dark. The solvent was evaporated and the yellow solid residue was dissolved in dichloromethane. The solution was washed with saturated aqueous potassium carbonate solution and then with water. The organic phase was dried over sodium sulfate. Upon addition of light petroleum a yellow precipitate was formed that was collected, washed twice with light petroleum and dried to afford the pure product as a yellow powder (21 mg, 0.014 mmol, 95 % yield [(C^N pz^N )Au(NHC-C4-NHC-AuCl)]PF6 (AuC4Au) Following the procedure described for AuC2Au, the compound was made from AuC4NH2 (34 mg, 0.033 mmol) and {MeBzim(Bz-4-CO2(C6F5))}AuCl (22 mg, 0.033 mmol) and obtained as a yellow powder (47 mg, 0.031 mmol, 95 % yield). Anal. Calcd for C60H62N8O2Au2ClPF6.7H2O (1627.7): C, 44.28; H, 4.71; N, 6.88. Found: C, 44.19; H, 3.57; N, 7.19 [(C^N pz^N )Au(NHC-C6-NHC-AuCl)]PF6 (AuC6Au) Following the procedure described for AuC2Au, the compound was made from AuC6NH2 (50 mg, 0.048 mmol, 1 eq.) and {MeBzim(Bz-4-CO2(C6F5))}AuCl (32 mg, 0.048 mmol, 1 eq.) and obtained as a yellow powder (47 mg, 0.031 mmol, 95 % yield). Anal. Calcd for
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